Long-term effects of motherfit group therapy in pre-(MOTHERFIT1) and post-partum women (MOTHERFIT2) with stress urinary incontinence compared to care-as-usual: study protocol of two multi-centred, randomised controlled trials.

Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2006-

Peer Group*; Exercise Therapy/*methods ; Pelvic Floor/*physiopathology ; Perinatal Care/*methods ; Pregnancy Complications/*prevention & control ; Urinary Incontinence, Stress/*prevention & control; Female ; Humans ; Multicenter Studies as Topic ; Netherlands ; Postpartum Period ; Pregnancy ; Pregnancy Complications/diagnosis ; Pregnancy Complications/etiology ; Pregnancy Complications/physiopathology ; Protective Factors ; Psychotherapy, Group ; Randomized Controlled Trials as Topic ; Risk Factors ; Time Factors ; Treatment Outcome ; Urinary Incontinence, Stress/diagnosis ; Urinary Incontinence, Stress/etiology ; Urinary Incontinence, Stress/physiopathology

Background: Stress urinary incontinence (SUI) is highly prevalent during pregnancy and after delivery. It is often associated with a failing pelvic floor, sphincteric and/or supportive system. Pelvic-floor-muscle training (PFMT) peri-partum has been proven effective for up to 1 year post-partum; however, its long-term effects are unknown. Group PFMT, given by a physiotherapist, has been proven to be as equally effective as individual therapy. Motherfit is a group-PFMT therapy with an emphasis on pelvic floor exercises, adherence and general fitness. Care-as-usual (CAU), if guideline driven, should, as first treatment option, consist of PFMT. Cost-effective strategies are of relevance, given the rise of health care costs. Motherfit group therapy has the potential to be cost-effective in women with urinary incontinence. Therefore, the objectives of the two current studies are: (1) to investigate whether intensive, supervised, pre-partum (MOTHERFIT1) or post-partum (MOTHERFIT2) pelvic-floor-muscle group therapy reduces 18-month post-partum severity of SUI compared to CAU and (2) whether MOTHERFIT1 OR MOTHERFIT 2 is more (cost-)effective compared to CAU.
Methods: Two multi-centred, randomised controlled trials (MOTHERFIT1, n = 150, MOTHERFIT2, n = 90) will be performed. Participants will be recruited by their midwife or gynaecologist during their routine check. Participants with SUI will receive either motherfit group therapy or CAU. Motherfit group therapy consists of eight group sessions of 60 min each, instructed and supervised by a registered pelvic physiotherapist. Motherfit group therapy includes instructions on pelvic floor anatomy and how to contract, relax and train the pelvic-floor muscles correctly and is combined with general physical exercises. Adherence during and after motherfit will be stimulated by reinforcement techniques and a mobile app. The primary outcome measure is the absence of self-reported SUI based on the severity sum score of the International Consultation on Incontinence Questionnaire Short Form (ICIQ-UI-SF) at 18 months post-partum. Secondary outcomes evaluate quality of life, subjective improvement and health care costs.
Discussion: The motherfit studies are, to our knowledge, the first studies that evaluate both long-term results and health care costs compared to CAU in pregnant and post-partum women with SUI. If motherfit is shown to be (cost-)effective, implementation in peri-partum care should be considered.
Trial Registration: Netherlands Trial Register, ID: NL5816 . Registered on 18 July 2016.

BMJ. 1999 Feb 20;318(7182):487-93. (PMID: 10024253)
Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(6):394-8. (PMID: 10614977)
Spine (Phila Pa 1976). 2000 Dec 15;25(24):3167-77. (PMID: 11124733)
Am J Obstet Gynecol. 2001 Jul;185(1):82-7. (PMID: 11483909)
Neurourol Urodyn. 2003;22(2):97-104. (PMID: 12579625)
Am J Obstet Gynecol. 2003 Jul;189(1):98-101. (PMID: 12861145)
Int Urogynecol J Pelvic Floor Dysfunct. 2003 Nov;14(5):296-304; discussion 304. (PMID: 14618304)
Gastroenterology. 2004 Jan;126(1 Suppl 1):S23-32. (PMID: 14978635)
Scand J Urol Nephrol. 2004;38(2):125-30. (PMID: 15204395)
Neurourol Urodyn. 2004;23(4):322-30. (PMID: 15227649)
Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5. (PMID: 17049716)
Scand J Caring Sci. 2007 Sep;21(3):305-12. (PMID: 17727542)
Med Sci Sports Exerc. 2007 Aug;39(8):1423-34. (PMID: 17762377)
Am J Obstet Gynecol. 2007 Dec;197(6):636.e1-6. (PMID: 18060960)
Int Urogynecol J Pelvic Floor Dysfunct. 2008 Jun;19(6):773-82. (PMID: 18204797)
J Eval Clin Pract. 2008 Oct;14(5):807-11. (PMID: 18462277)
Neurourol Urodyn. 2009;28(5):411-5. (PMID: 19214996)
J Eval Clin Pract. 2009 Apr;15(2):341-5. (PMID: 19335495)
Int Urogynecol J Pelvic Floor Dysfunct. 2009 Sep;20(9):1037-45. (PMID: 19444368)
BMC Womens Health. 2009 Sep 14;9:26. (PMID: 19751517)
Int Urogynecol J. 2010 Jan;21(1):5-26. (PMID: 19937315)
J Clin Epidemiol. 2010 Jul;63(7):760-766.e1. (PMID: 20056385)
Obstet Gynecol. 2010 Mar;115(3):618-28. (PMID: 20177295)
J Wound Ostomy Continence Nurs. 2010 Mar-Apr;37(2):187-92. (PMID: 20228661)
Neurourol Urodyn. 2010;29 Suppl 1:S13-7. (PMID: 20419794)
Med Sci Sports Exerc. 2011 Jul;43(7):1334-59. (PMID: 21694556)
Cochrane Database Syst Rev. 2011 Dec 07;(12):CD009508. (PMID: 22161451)
Neurourol Urodyn. 2012 Jun;31(5):642-5. (PMID: 22415626)
Scand J Caring Sci. 2013 Jun;27(2):406-13. (PMID: 22924517)
Cochrane Database Syst Rev. 2012 Oct 17;10:CD007471. (PMID: 23076935)
Int Urogynecol J. 2013 Sep;24(9):1473-9. (PMID: 23229419)
Neurourol Urodyn. 2013 Sep;32(7):974-9. (PMID: 23281067)
Value Health. 2014 Jan-Feb;17(1):5-14. (PMID: 24438712)
BJOG. 2015 Jun;122(7):954-62. (PMID: 25039427)
Neurourol Urodyn. 2015 Nov;34(8):747-51. (PMID: 25154378)
Prim Health Care Res Dev. 2015 Jul;16(4):377-82. (PMID: 25273552)
BJOG. 2016 May;123(6):1022-9. (PMID: 25846816)
Neurourol Urodyn. 2015 Sep;34(7):615-21. (PMID: 25998493)
Value Health. 2016 Jun;19(4):343-52. (PMID: 27325326)
Int Urogynecol J. 2017 Mar;28(3):351-359. (PMID: 27613622)
Neurourol Urodyn. 2019 Jan;38(1):63-80. (PMID: 30375056)
Neurourol Urodyn. 1995;14(2):131-9. (PMID: 7780440)

80-84300-98-72001 ZonMw

Keywords: Cost-effective; Group therapy; Motherfit; Pelvic-floor-muscle training; Peri-partum; Post-partum; Pre-partum; Pregnancy; Randomised controlled trial; Stress urinary incontinence

Date Created: 20190427 Date Completed: 20191212 Latest Revision: 20200225

20250114

PMC6485130

10.1186/s13063-019-3331-6

31023381